Company intelligence / Profile preview

Intellikine

La Jolla, California, United Statesbiospace.com ↗

Ownership: Private
Employees: ~36
Development stage: Other

Overview

Intellikine advanced three small molecule kinase inhibitor programs targeting the PI3K/mTOR pathway into human clinical trials within four years of founding. Its most advanced asset at acquisition was INK128 (a TORC1/2 inhibitor) in multiple Phase 1 studies for solid tumors and hematologic cancers. INK1117 (a PI3K alpha inhibitor) had an approved IND with plans for Phase 1 initiation. A third program—INK1197/IPI‑145—was licensed to Infinity Pharmaceuticals and reached Phase III trials in chronic lymphocytic leukemia after the acquisition.

Therapeutic areas: ImmunologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Infinity Pharmaceuticals – partnership/licensing for PI3K delta/gamma inhibitors including INK1197/IPI‑145Contract research organization(s) in China for drug development supportMultiple Myeloma Research Foundation & Polycystic Kidney Disease Foundation provided support/funding for specific indications/programs

Beyond the preview

Go deeper on Intellikine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intellikine.

Explore the full profile